Company profile · Biotech & medical
OBI Pharma
台灣浩鼎生技股份有限公司 · 4174
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
OBI Pharma engages in new drug research and development.[1]
The company develops novel therapeutic agents for patients with unmet medical needs, focusing on next-generation antibody-drug conjugates (ADCs) and proprietary technologies such as the Obrion platform, GlycOBI glycan-conjugation, and GlycOBI DUO dual-payload platforms.[2]
Its pipeline features products including anti-TROP2 (OBI 902), Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3 Bs-Dual Payload ADC (OBI 221), and HYProtecan.[2]
The company is based in Taipei, Taiwan.[1]
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$2m | -58.7% | +40.8% |
2024-11 to 2026-10, monthly revenue.
Foreign investors
| Last 20 trading days | Net |
|---|---|
| 2026-10-12 to 2026-11-10 | +NT$13m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
Facts
| Full English name | OBI Pharma, Inc. |
|---|---|
| Chinese name | 台灣浩鼎生技股份有限公司 |
| Stock code | 4174 (TPEx) |
| Industry | Biotech & medical |
| Founded | 29 Apr 2002 |
| Listed | 23 Mar 2015 |
| Paid-in capital | NT$1.3bn |
| Chairman | 梁賡義 |
| President | 陳雅琪 |
| Headquarters | 6F., No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist. Taipei City 115011, Taiwan R.O.C |
| Website | https://www.obipharma.com |
| Official business description | 新藥研發 |
Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- MOPS 公司基本資料 台灣浩鼎生技股份有限公司 · mops · retrieved 04 Nov 2026
- HOME - OBI Pharma · website · retrieved 04 Nov 2026
Using it at work? Join the team-plan waiting list